The present invention discloses a S-adenosyl-L-methionine δ24-sterol-C-methyltransferase mutant C24MTgm-M11. Strain MG1655 (ΔptsG ΔfumAC ΔfumB, panD, aspA, C24MTgm) is constructed based on the polynucleotide encoding the enzyme mutant. Strain MG1655 (Δpts GΔfumAC ΔfumB, panD, aspA, C24MTgm-M11) can produce 480 mg/L 3-aminoisobutyric acid under shake flask fermention. Compared to the wild type strain C24MTgm, the strain containing mutant C24MTgm-M11 has a significantly improved ability to produce 5.8 times' 3-aminobutyric acid.

The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.

The present invention relates to a recombinant yeast strain having sterol productivity, a preparation method therefor and a use thereof, and more specifically, to a recombinant yeast strain capable of producing cholesterol and cholesterol precursors in a high yield through the deletion of ERG5 and ERG6 genes and the introduction of DHCR24 and DHCR7 genes by codon-optimizing same in multiple or with a codon context method; and a production method therefor and a use thereof. In addition, disclosed are: a method for producing a recombinant yeast strain with increased production yields of cholesterol and cholesterol precursors by the additional introduction of gene tHMG1, ERG2, ERG3, ERG27, or UPC2-1 in the prepared recombinant yeast strain; and a use thereof

The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.

The present invention discloses a S-adenosyl-L-methionine 24-sterol-C-methyltransferase mutant C24MTgm-M11. Strain MG1655 (ptsG fumAC fumB, panD, aspA, C24MTgm) is constructed based on the polynucleotide encoding the enzyme mutant. Strain MG1655 (pts GfumAC fumB, panD, aspA, C24MTgm-M11) can produce 480 mg/L 3-aminoisobutyric acid under shake flask fermentation. Compared to the wild type strain C24MTgm, the strain containing mutant C24MTgm-M11 has a significantly improved ability to produce 5.8 times' 3-aminobutyric acid.

The present invention relates to genetically-modified oleaginous yeasts for producing non-native sterols at commercially useful levels, especially for example in providing sterols individually or as a mixture in an artificial dietary composition for honeybees or other insects or animals. For this purpose, an oleaginous yeast, e.g. Yarrowia lipolytica, may be employed wherein the yeast has reduced production of ergosterol compared with a wild-type oleaginous yeast or is incapable of producing ergosterol and is provided with a sterol surrogate to aid growth. From such yeast, however, other yeast may be engineered which retain useful sterol production without need for a sterol surrogate, e.g. production of sterol mixtures in which 24-methylenecholesterol or campesterol is the dominant sterol.